In summary, this peptide‐conjugated PDT‐based nanoparticle significantly enhances antitumor immune responses by targeting HER2 protein degradation, inducing ICD, activating dendritic cells, and enhancing cytotoxic T cell activity, thereby providing a new therapeutic approach for breast cancer treatment. Here, ERBB2 is linked to breast carcinoma.